 Biocept Inc NASDAQ:BIOC, the diagnostics-focused group, swung to a profit in its third quarter, recovering from the loss it reported in the corresponding period last year, thanks to a 165 increase in revenue on the back of increased RT-PCR COVID-19 testing. For the three months to September 30, the company posted net income of 427,000 compared to a loss of 4.9 million in 3Q, 2020. 